TABLE 1.

Clinical recommendations for the use of anticoagulants in patients with COVID‐19.

Patients	ASH 47 , 48	NIH d	ISTH 49
Non‐hospitalized	–	Did not recommend routine prophylaxis	Did not recommend routine prophylaxis
After discharge	–	Did not recommend prolonged prophylaxis	If there is a high risk of thrombosis and low risk of hemorrhage, apply LMWH or DOAC for 30 days
Critically ill	Prophylactic‐dose a anticoagulation over intermediate‐dose b or therapeutic‐dose c anticoagulation	Prophylactic‐dose anticoagulation	Prophylactic‐dose anticoagulation with LMWH If the patient was high risk, apply half–therapeutic‐dose LMWH
Non–critically ill	Therapeutic‐dose over prophylactic‐dose anticoagulation in acutely ill who do not have suspected or confirmed VTE or any other indication for anticoagulation	Prophylactic‐dose anticoagulation	Prophylactic‐dose anticoagulation with LMWH

Abbreviations: ASH, American Society of Hematology; COVID‐19, coronavirus disease 2019; DOAC, direct‐acting oral anticoagulants; ISTH, International Society of Thrombosis and Hemostasis; LMWH, low‐molecular‐weight heparin; NIH, National Institute of Health; UFH, unfractionated heparin.

^a Enoxaparin (30–40 mg subcutaneous (s.c.) not exceeding <0.7 mg/kg/day or 30–40 mg s.c. not exceeding <0.4 mg/kg/12 h), UFH (5000 IU s.c. 3 times a day or 5000–7500 IU s.c. 3 times a day), or Fondaparinux (2.5 mg s.c. one time a day for 5–10 days).

^b Enoxaparin (≥0.4 but ≤0.7 mg/kg/12 h) or UFH (5000 IU s.c. 3 times a day or 5000–7500 IU s.c. 3 times a day).

^c Enoxaparin (≥0.7 mg/kg/12 h, ≥0.7 mg/kg/day in patients with chronic kidney disease, or >1.4 mg/kg/day), UFH (bolus intravenously followed by drip, with activated partial thromboplastin time guided dose adjustments), or Bivalirudin (bolus intravenously followed by drip, with activated clotting time guided dose adjustments).

^d https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic‐therapy/.